In an attempt to understand the pathogenesis of corneal changes and conjunctival scarring in trachoma, which are responsible for blindness in some 7 million people worldwide, the surface expression of major histocompatibility complex class II antigens on conjunctival epithelial cells was sought in patients with different clinical features of the disease. Class II expression was significantly associated with active (inflammatory) trachoma, but an independent association with corneal pannus or conjunctival scarring could not be shown. Longitudinal data suggest that class II expression may antedate clinically active disease and persist after it has resolved.
Trachoma remains a major cause of blindness second only to cataract in many parts of the world. It is believed to affect some 500 million people, of whom 7 million are blind.' In its early stages trachoma is a chronic follicular conjunctivitis affecting principally the subtarsal conjunctiva, often with corneal disease in the form of punctate keratitis or vascular infiltration (pannus), which is occasionally so extensive as to impair vision.2 Chlamydia trachomatis can often be isolated from conjunctival swabs or scrapings at this stage.3 As the inflammatory changes subside they are frequently replaced by conjunctival scarring and fibrosis, which, if severe, may lead to distortion of the lid margin, entropion, and hence blindness secondary to prolonged corneal trauma. C trachomatis can rarely be isolated from patients with scarring disease.
In endemic areas the early stages of trachoma are seen in young children, whereas conjunctival scarring is seen principally in adults in whom it seems to progress in severity over time. 4 The pathogenesis of pannus and conjunctival scarring in trachoma remain unclear. There is evidence that in primate models both may be immunopathological in origin as they were only seen in animals which had been repeatedly infected or immunised.56 Trachoma vaccine trials in man showed no evidence that more severe pannus or scarring followed immunisation, although in two of these trials the incidence of trachoma was reported to be higher in the vaccinated group.78 A migrant study suggested that conjunctival scarring does not progress in those who leave an endemic area, implying that continued exposure to C trachomatis is a prerequisite.'
It is not clear why scarring should progress in subjects from whom the organism cannot be isolated. It has been proposed that such patients may have latent chlamydial infections, and chlamydial antigen has been detected in a minority of patients with conjunctival scarring.'1 An alternative hypothesis is that an initial chlamydial infection may trigger certain immunological changes in the conjunctival epithelium, leading to chronic immunopathological damage. This study was approved by the joint Gambia Government/Medical Research Council ethical committee.
All subjects with clinically active trachoma were given a course of supervised treatment comprising a 10 day course of oral antibiotics (tetracycline or, in the case ofchildren aged less than 6 years, erythromycin) and a four week course of 1% tetracycline ointment applied to both eyes twice daily.
COLLECTION AND PROCESSING OF SPECIMENS
Swabs for detection of MHC class II expression were taken from the upper subtarsal conjunctiva by firmly rubbing it three to four times with a cotton wool tipped swab (MW 142, Medical Wire Co). The swab was immediately expressed into 1 ml of transport medium (phosphate buffered saline + 5% bovine serum albumin), and stored on ice for up to hours, after which it was divided into five equal portions and cytocentrifuged. Cytocentrifuge preparations were air dried, fixed in acetone, and transported with desiccant at -20°C to Southampton.
Swabs for detection of chlamydial antigen were collected as described above, at least one week before collecting swabs for MHC class II detection. Swabs and transport medium were formed from alkaline phosphatase pre-mixed with a monoclonal antibody to alkaline phosphatase. Specimens were washed three times with buffer between each of these incubation stages. The final reaction product was shown using Fast Red TR to give precise localisation of the alkaline phospatase label in conjunction with haematoxylin counterstain. All primary and secondary reagents were used at previously determined working dilutions and appropriate controls were included for non-specific binding of the primary reagent and also of the reporter system. Specimens were read blind by a single observer (MEW) and reported as negative or positive grade 1, 2, or 3, depending on the number of positive cells and the intensity of staining. Grade 1 implied that less than 40% of cells expressed HLA DR, grade 2 that between 40% and 80% expressed HLA DR, and grade 3 that more than 80% of epithelial cells expressed HLA DR.
Detection of chlamydial antigen Chlamydial antigen was assayed using the Boots-Celltech IDEIA amplified enzyme immunoassay, according to the manufacturer's instructions, as described previously.'0
Results
The age and sex distribution of the different categories of patient are shown in tables 1 and 2. It was not possible to match subjects with and without conjunctival scarring by age, because this phenomenon is rare in children aged less than 10 years in Jali, and the number of children aged more than 10 years with active disease is small.
MHC CLASS II EXPRESSION AND CLINICAL FINDINGS
Equivalent results were obtained with the two monoclonal antibodies used. There was no difference between the sexes in the prevalence of figure) . This difference is highly significant (X2 = 13-2; p < 0-001).
The association between MHC class II expression and four clinical signs (follicular conjunctivitis, papillary hypertrophy, pannus and conjunctival scarring) is shown in table 3. As these are all continuous variables, results have been combined from subjects with and without active trachoma. Increasing follicular score, papillary hypertrophy, and pannus were all strongly associated with increased expression of MHC class II, but these signs of active disease were all closely interrelated. Logistic regression analysis suggested papillary hypertrophy score to be the strongest predictor of class II expression, with no additional effect of any other sign. Table 4 shows the association between conjunctival scarring and class II expression in subjects aged 5 years and over; younger subjects have been excluded because scarring was not seen below this age, and results have been pooled for subjects with and without active trachoma for the reasons given above. Once again, papillary score is a strong confounding variable. Among those with a papillary hypertrophy score of <2, there is a suggestion that class II expression is more common in those with scarring ( negative for class II expression, only six (21 %) had active disease at the previous or subsequent survey. This implies that class II expression, rather than being a non-specific finding in this community, may precede active trachoma and persist after it has resolved, although the difference between the two groups does not quite achieve significance (six of 10 v six of 28; X2 = 3-45;0-1 > p > 0-05).Wehaveobserved persistent class II expression in the conjunctival epithelium ofone subject on two occasions six months apart, his last recorded episode of active disease having been eight months before the first sample was taken.
EFFECT OF TREATMENT ON EXPRESSION OF MHC CLASS II
We studied the effect of the antimicrobial treatment of trachoma on the expression of MHC class II by the conjunctival epithelium in 21 subjects. Nine (43%) of these subjects remained clinically active at the time the second specimen was taken (six months after the completion of treatment), although all were negative for chlamydial antigen. Fourteen (67%) continued to express MHC class II: seven of nine with clinically active disease (78%) and seven of 12 (58%) who were clinically cured.
Discussion
We have shown that MHC class II antigens are commonly expressed by conjunctival epithelial cells in patients with active trachoma. Class II expression is correlated with the severity of follicular changes and papillary hypertrophy, and with the presence ofpannus. The strongest predictor seems to be the presence of papilla.y hypertrophy, but an effect due to pannus or follicular changes cannot be excluded as the three variables are strongly correlated and the number of subjects studied relatively small. Our results suggest that class II expression is more prevalent among patients with active disease who have pannus than among those who do not, but the difference does not reach significance. It will be necessary to study larger numbers of patients to elucidate this relationship more clearly. We are most grateful to Dr B M Greenwood for his support and encouragement; to Dr R G Whitehead and the staff of the MRC Dunn Nutrition Unit, Keneba, for providing accommodation and laboratory facilities; to Bakary Dibba and Almami Janneh for their help with the field surveys; and to the people of Jali for their good humoured cooperation. This study was supported by the Edna McConnell Clark Foundation.
